Combined Tumor-Based IBRCA1/2/I and ITP53/I Mutation Testing in Ovarian Cancer

Somatic/germline BRCA1/2 mutations (m)/(likely) pathogenic variants (PV) (s/gBRCAm) remain the best predictive biomarker for PARP inhibitor efficacy. As >95% of high-grade serous ovarian cancers (HGSOC) have a somatic TP53m, combined tumor-based BRCA1/2 (tBRCA) and TP53 mutation testing (tBRCA/TP...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	International journal of molecular sciences 2023-07, Vol.24 (14)
Hauptverfasser:	Borcoman, Edith, Santana dos Santos, Elizabeth, Genestie, Catherine, Pautier, Patricia, Lacroix, Ludovic, Caputo, Sandrine M, Cabaret, Odile, Guillaud-Bataille, Marine, Michels, Judith, Auguste, Aurelie, Leary, Alexandra, Rouleau, Etienne
Format:	Artikel
Sprache:	eng
Schlagworte:	Medical tests Ovarian cancer Tumor proteins
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!